Having experienced significant challenges after the outbreak of COVID-19, the healthcare industry in China is on the way to recovery. Companies are facing the "new normal" and adapting to the new dynamics. How is the biopharma industry, in particular, dealing with the crisis and driving growth and innovation going forward? AmCham Shanghai Healthcare Committee invites you to a discussion on how the biopharma companies are manging the risks, accelerating the digital transformation and innovation, and what are the latest investment trends in biopharma on July 1st, from 10:00 am to 11:30 am. The session consists of presentations as well as a panel discussion. The discussion will be facilitated by Greg Scott, Founder & Chairman of ChinaBio® Group and the Chair of AmCham Shanghai Healthcare Committee.